ESEdward M. Schaeffer

Edward M. Schaeffer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edward M. Schaeffer has a total of 521 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure 2 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images

    by Mohamed Omar, Zhuoran Xu, Sophie B. Rand, Mohammad K. Alexanderani, Daniela C. Salles, Itzel Valencia, Edward M. Schaeffer, Brian D. Robinson, Tamara L. Lotan, Massimo Loda, et al.

    Supplementary Figure 2. Comparison of Cellular Composition by TMPRSS2:ERG Fusion Status and Gleason Score in the TCGA Cohort. The average immune, neoplastic, and stroma to neoplastic ratios across two categories of TMPRSS2:ERG fusion status (Negative and Positive) stratified by Gleason score (=8). The immune ratio panel shows the proportion of immune cells, the neoplastic ratio panel displays the proportion of neoplastic cells, and the stroma to neoplastic ratio panel depicts the relative abundance of stromal to neoplastic cells within the analyzed tissue sections. Red bars represent cases with a Gleason score of less than 8, while blue bars represent cases with a Gleason score of 8 or higher.

  • Open Access

    Supplementary Tables 1 and 2 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images

    by Mohamed Omar, Zhuoran Xu, Sophie B. Rand, Mohammad K. Alexanderani, Daniela C. Salles, Itzel Valencia, Edward M. Schaeffer, Brian D. Robinson, Tamara L. Lotan, Massimo Loda, et al.

    Supplementary Table 1. Performance metrics for the ERG prediction model in the TCGA testing cohort. The table shows the model’s performance in the TCGA testing cohort consisting of 59 whole slide images using different thresholds derived from the training data. PPV: positive predictive value; NPV: negative predictive value; MCC: Matthews Correlation Coefficient. Supplementary Table 2. Performance metrics for the ERG prediction model in the natural history cohort. The table shows the model’s performance in the natural history cohort consisting of 314 whole slide images using different thresholds derived from the training data. PPV: positive predictive value; NPV: negative predictive value; MCC: Matthews Correlation Coefficient.

  • Open Access

    Supplementary Figure 1 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images

    by Mohamed Omar, Zhuoran Xu, Sophie B. Rand, Mohammad K. Alexanderani, Daniela C. Salles, Itzel Valencia, Edward M. Schaeffer, Brian D. Robinson, Tamara L. Lotan, Massimo Loda, et al.

    Supplementary Figure 1. Progression-free survival in the TCGA cohort using the cellular composition of the whole slide images. Kaplan-Meier curves showing the association between the fraction of each nuclear type and progression-free survival. The fraction of each cell type was calculated by dividing the absolute number of that cell type over the number of all cells in the whole slide. The stromal to neoplastic ratio was calculated by dividing the number of stromal cells by that of neoplastic cells in the whole slide. These fractions were then then binarized into high versus low using maximally selected log-rank statistics.

  • Open Access

    The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ ( PATROL) study

    by Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, et al.

    Background: Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53 . However, the optimal early detection strategy for gPV carriers, including use of age‐adjusted PSA thresholds and prostate imaging may be refined. and as a means to investigate novel biomarkers. Study Design: ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) is a multicentre, prospective early detection study for individuals at increased risk for PCa due to carrying a gPV in a PCa risk gene. Endpoints: The primary endpoint is to determine the positive predictive value of pre‐defined age‐directed prostate‐specific antigen (PSA) level thresholds and prostate‐specific imaging, e.g., multiparametric magnetic resonance imaging (MRI) for clinically significant PCa on biopsy for individuals at risk of PCa due to a gPV. Exploratory endpoints include characterising clinicopathological characteristics of PCa and patient‐reported outcomes. Biospecimens will be collected to evaluate emerging clinical and research biomarkers. Patients and Methods: Key eligibility includes: individuals aged ≥40 years who carry a gPV in an eligible gene, who have no prior diagnosis of PCa, do not have another active malignancy, and provide informed consent. Study procedures include annual physical examination and PSA. Imaging with MRI is optional at baseline and recommended if the PSA level is above the protocol‐recommended PSA level threshold. Participants will be offered prostate biopsy for any clinical concern, PSA level >1.0 ng/mL if aged 1.5 ng/mL if aged 50–59 years; PSA level >2.0 ng/mL if aged ≥60 years. If PCa is diagnosed, clinical care is determined by the participant and treating physician. If opting for active surveillance, study procedures will be collected annually for 10 years or until definitive treatment. If definitive treatment, study procedures will be collected for an additional 1 year. Long‐term clinical outcomes will be collected annually until the study closes.


  • Predictors of fluoroquinolone-resistant bacterial colonization prior to prostate biopsy: a secondary analysis of two randomized trials

    by Daniel Barbakoff, Gal Wald, Mary Oakley Strasser, Rebecca Yu, Joshua Winograd, Mitchell Huang, Conor B. Driscoll, Nicole Handa, Andrew Vickers, Edward M. Schaeffer, et al.

    The prevalence of fluoroquinolone resistant (FQR) rectal bacterial colonization ranges from 15-20%, and FQR colonization increases the risk of prostate biopsy infectious complications. FQR bacteria have been identified in 50% of prostate biopsy infectious complications. However, predictors of FQR remain unclear, so we aimed to elucidate these characteristics. A secondary analysis of two multicenter clinical trials (NCT04815876 and NCT04843566) comprising 11 sites was conducted on men who underwent rectal swab cultures prior to prostate biopsy. Rectal swab cultures were examined to identify FQR bacteria and factors associated with post-biopsy infections. Sites with fewer than 30 rectal swab results were aggregated. Multivariable logistic regression was used to identify whether age, race, ethnicity, diabetes, smoking history, or site were associated with FQR colonization. FQR bacterial colonization was identified in 145 (16%, 95% CI: 13%, 18%) of 925 patients. One site within the same metropolitan area as the reference site had increased odds of FQR colonization [OR 3.68 (CI: 1.98, 6.83, p < 0.001)]. Transrectal biopsy infection risk increased with FQR rectal bacteria (3.9% vs. 0.8%; risk difference 3.2%; 95% CI: -1.3%, 7.5%; p = 0.017). There was an insignificantly increased odds of FQR colonization for Asian men (OR 1.94, 95% CI: 0.92, 3.89; p = 0.070). FQR rectal colonization was associated with higher rates of post-TR biopsy infection despite targeted prophylaxis. FQR colonization rates differed significantly across trial sites. Future research should continue to identify FQR predictors and their underlying causal pathways to reduce the risk of infectious complications.

  • Open Access

    A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR

    by Yang Yi, Yanqiang Li, Rui Wang, Xufen Yu, Qi Liu, Chaehyun Yum, Yang Zhang, Yuanyuan Qiao, Aileen Szczepanski, Siqi Wu, et al.

    Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a widespread modification in metazoans. Cumulative evidence has revealed the altered A-to-I editing profiles in cancers, but the underlying mechanism remains unclear. Here, we discover the well-known histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) as an unexplored ADAR interactor and editing regulator in prostate cancer (PCa). Through competing with interleukin enhancer binding factor 2 (ILF2) for ADAR1 binding, EZH2 reshapes the substrate selectivity of ADAR1 and thus exhibits a bidirectional role in editing regulation. Moreover, EZH2 depletion induces the translational repression of transportin-1 (TRN1), which further results in the accumulation of cytoplasmic ADAR1p110 isoform to protect many oncogenic transcripts from degradation. Consistently, depletion of ADAR1 dramatically enhances the sensitivity of cancer cells and tumors to EZH2 selective degraders. Collectively, our study sheds new light on a link between two layers of epigenetic regulations at histone modification and RNA editing levels, demonstrates a previously uncharacterized role of EZH2 in RNA editing and mRNA stability independently of its lysine methyltransferase activity, and reveals the significance of EZH2-ADAR1 cascade in governing RNA editing and mRNA stability, which may provide additional perspectives for the advancement of EZH2-targeting cancer therapies.


  • Open Access

    Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling

    by Yongyong Yang, Ting-You Wang, Joshua Fry, Yingming Li, Qingshu Meng, Qingxiang Guo, Nathan E. Patchen, Kyle H. White, Abhirami Ramakrishnan, Yanan Ren, et al.

    LncRNAs have emerged as pivotal regulators in the development and progression of various human cancers. However, understanding the precise mechanisms by which lncRNAs influence cancer progression remains a substantial challenge, largely due to their cell type- and tissue-specific expression patterns and the lack of well-defined functional domains or motifs. In this study, we investigate the complex interplay between super-enhancers and lncRNAs through a comprehensive analysis of lncRNA expression in a cohort of metastatic castration-resistant prostate cancer patients. Our analysis identifies 1344 lncRNAs, among which an antisense lncRNA in the IGF1R locus named IGF1R-AS1 displayed the strongest super-enhancer association. Through pan-cancer transcriptome analysis, we find that IGF1R-AS1 is specifically transcribed in tumor specimens and is overexpressed in prostate and lung cancers. Notably, we reveal a non-canonical trans -acting role for IGF1R-AS1 whereby it interacts with chromatin remodeling complexes and architectural proteins to facilitate long-range chromatin looping between distal MYC enhancers and its promoter, leading to MYC overexpression and enhanced tumorigenicity. Collectively, our findings elucidate a mechanism by which a tumor-specific trans -acting lncRNA modulates oncogenic MYC expression through long-range chromatin interactions, suggesting IGF1R-AS1 may play an important role in the pathogenesis of MYC-driven malignancies.


  • Open Access

    Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis

    by Conor B. Driscoll, Nicole Handa, Mitchell M. Huang, Adam B. Murphy, Jim C. Hu, Edward M. Schaeffer

    Purpose: Non-White patients are poorly represented in prostate cancer trials. MRI PI-RADS scoring was developed in primarily White populations, but prostate cancer differs in non-White men. We aimed to explore differences in PI-RADS calibration for Asian and Black men. Materials and methods: This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher’s exact and logistic regression. Results: Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, P = 0.004) and clinically significant prostate cancer (60% vs. 27%, P = 0.003) and Asian men had decreased rates of overall (0% vs. 47%, P = 0.004) and clinically significant prostate cancer (0% vs. 27%, P = 0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, P = 0.009) and clinically significant prostate cancer (OR 1.20, P = 0.004) and Asian men had lower odds of overall (OR 0.79, P = 0.01) but not clinically significant prostate cancer (OR 0.94, P = 0.5). Conclusions: Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men. Trial Registration: Registered at ClinicalTrials.gov ( NCT04843566 , https://clinicaltrials.gov/study/NCT04843566 ).


  • Open Access

    Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.

    by Conor Driscoll, Nicole Handa, Mitchell Huang, Adam Murphy, Jim Hu, Edward Schaeffer

    Purpose : Non-White patients are poorly represented in prostate cancer trials. MRI PI-RADS scoring was developed in primarily White populations, but prostate cancer differs in non-White men. We aimed to explore differences in PI-RADS calibration for Asian and Black men. Materials and Methods: This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher’s exact and logistic regression. Results: Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, P =0.004) and clinically significant prostate cancer (60% vs. 27%, P =0.003) and Asian men had decreased rates of overall (0% vs. 47%, P =0.004) and clinically significant prostate cancer (0% vs. 27%, P =0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, P =0.009) and clinically significant prostate cancer (OR 1.20, P =0.004) and Asian men had lower odds of overall (OR 0.79, P =0.01) but not clinically significant prostate cancer (OR 0.94, P =0.5). Conclusions: Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men. Source of Funding: Supported by the NCI (5R01CA241758-05). Trial Registration: Registered at ClinicalTrials.gov (NCT04843566, https://clinicaltrials.gov/study/NCT04843566).


  • Open Access

    Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making

    by Sarah Sandlow, Samuel Carbunaru, Zequn Sun, Bernice Ofori, Yingzhe Liu, Eric Li, Courtney M. P. Hollowell, Patricia Vidal, Kent T. Perry, Hiten D. Patel, et al.

    Prostate Imaging Reporting and Data System (PIRADS) v2.1 scoring with multiparametric MRI (mpMRI) has a pooled 90% negative predictive value (NPV). PSA density (PSAD) ≤0.15ng/ml/cm3 has been shown to enhance mpMRI's NPV in non-Black men. Populations with higher disease prevalence are known to have lower NPVs. Given that Black men have higher PCa prevalence, we evaluate sensitivity and NPV of mpMRI in Black vs. non-Black men to assess possible mpMRI performance differences. As an exploratory objective, we investigate PSAD thresholds providing ≥90% sensitivity in Black men. We prospectively recruited Black and non-Black men referred to outpatient urology clinics for abnormal PSA or prostate exam in three similar biomarker validation studies from 2017-23 before MRI-informed diagnostic prostate biopsy. We combined the research cohorts with a retrospective clinical cohort of clinically similar Black and non-Black men from one academic institution who also underwent mpMRIs and MRI-informed biopsies. MRIs were scored using PIRADS version 2.0 or 2.1. Our analysis included 286 Black men and 965 non-Black men with PSA ≤15.0ng/ml. PIRADS <3 had an NPV of 77.1% versus 87.6% and a sensitivity of 90.7% vs. 96.3% for GG2-5 PCa in Black versus non-Black men, respectively (both p <0.05). Using PSAD ≥0.09 for Black men with PIRADS 1-2 lesions increased sensitivity to 92.9%. PIRADS <3 has a lower NPV and sensitivity in Black men. For negative prostate MRIs, PSAD ≥0.09 may be a better threshold for safe biopsy deferral in Black men to maintain a ≥90% sensitivity.